Research ExplorerPublicationsAllogeneic hematopoietic stem cell transplantation in patien...

Allogeneic hematopoietic stem cell transplantation in patients aged 60-79 years in Germany (1998-2018): a registry study

Standard

Allogeneic hematopoietic stem cell transplantation in patients aged 60-79 years in Germany (1998-2018): a registry study. / Weller, Jan Frederic; Lengerke, Claudia; Finke, Jürgen; Schetelig, Johannes; Platzbecker, Uwe; Einsele, Hermann; Schroeder, Thomas; Faul, Christoph; Stelljes, Matthias; Dreger, Peter; Blau, Igor W; Wulf, Gerald; Tischer, Johanna; Scheid, Christoph; Elmaagacli, Ahmet; Neidlinger, Helga; Flossdorf, Sarah; Bornhäuser, Martin; Bethge, Wolfgang; Fleischhauer, Katharina; Kröger, Nicolaus; De Wreede, Liesbeth C; Christopeit, Maximilian.

In: HAEMATOLOGICA, Vol. 109, No. 2, 01.02.2024, p. 431-443.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Weller, JF, Lengerke, C, Finke, J, Schetelig, J, Platzbecker, U, Einsele, H, Schroeder, T, Faul, C, Stelljes, M, Dreger, P, Blau, IW, Wulf, G, Tischer, J, Scheid, C, Elmaagacli, A, Neidlinger, H, Flossdorf, S, Bornhäuser, M, Bethge, W, Fleischhauer, K, Kröger, N, De Wreede, LC & Christopeit, M 2024, 'Allogeneic hematopoietic stem cell transplantation in patients aged 60-79 years in Germany (1998-2018): a registry study', HAEMATOLOGICA, vol. 109, no. 2, pp. 431-443. https://doi.org/10.3324/haematol.2023.283175

APA

Weller, J. F., Lengerke, C., Finke, J., Schetelig, J., Platzbecker, U., Einsele, H., Schroeder, T., Faul, C., Stelljes, M., Dreger, P., Blau, I. W., Wulf, G., Tischer, J., Scheid, C., Elmaagacli, A., Neidlinger, H., Flossdorf, S., Bornhäuser, M., Bethge, W., ... Christopeit, M. (2024). Allogeneic hematopoietic stem cell transplantation in patients aged 60-79 years in Germany (1998-2018): a registry study. HAEMATOLOGICA, 109(2), 431-443. https://doi.org/10.3324/haematol.2023.283175

Vancouver

Weller JF, Lengerke C, Finke J, Schetelig J, Platzbecker U, Einsele H et al. Allogeneic hematopoietic stem cell transplantation in patients aged 60-79 years in Germany (1998-2018): a registry study. HAEMATOLOGICA. 2024 Feb 1;109(2):431-443. https://doi.org/10.3324/haematol.2023.283175

Bibtex

@article{cdb8782b8bb248baa9fdb82cbfe8de7d,
title = "Allogeneic hematopoietic stem cell transplantation in patients aged 60-79 years in Germany (1998-2018): a registry study",
abstract = "Incidences of diseases treated with transplantation frequently peak at higher age. The contribution of age to total risk of transplantation has not been estimated amidst an aging society. We compare outcomes of 1,547 patients aged 70-79 years and 9,422 patients aged 60-69 years transplanted 1998-2018 for myeloid, lymphoid and further neoplasia in Germany. To quantify the contribution of population mortality to survival, we derive excess mortality based on a sex-, year- and agematched German population in a multistate model that incorporates relapse and graft-versus-host-disease (GvHD). Overall survival, relapse-free survival (RFS) and GvHD-free-relapse-free survival (GRFS) is inferior in patients aged 70-79 years, compared to patients aged 60-69 years, with 36% (95% Confidence Interval [CI]: 34-39%) versus 43% (41-44%), 32% (30- 35%) versus 36% (35-37%) and 23% (21-26%) versus 27% (26-28%) three years post-transplant (P<0.001). Cumulative incidences of relapse at three years are 27% (25-30%) for patients aged 70-79 versus 29% (29-30%) (60-69 years) (P=0.71), yet the difference in non-relapse mortality (NRM) (40% [38-43%] vs. 35% [34-36%] in patients aged 70-79 vs. 60-69 years) (P<0.001) translates into survival differences. Median OS of patients surviving >1 year relapse-free is 6.7 (median, 95% CI: 4.5-9.4, 70-79 years) versus 9 (8.4-10.1, 60-69 years) years since landmark. Three years after RFS of one year, excess NRM is 14% (95% CI: 12-18%) in patients aged 70-79 versus 12% [11-13%] in patients aged 60-69, while population NRM is 7% (6-7%) versus 3% (3-3%). Mortality for reasons other than relapse, GvHD, or age is as high as 27% (24-29%) and 22% (22-23%) four years after transplantation. In conclusion, survival amongst older patients is adequate after allogeneic stem cell transplantation.",
author = "Weller, {Jan Frederic} and Claudia Lengerke and J{\"u}rgen Finke and Johannes Schetelig and Uwe Platzbecker and Hermann Einsele and Thomas Schroeder and Christoph Faul and Matthias Stelljes and Peter Dreger and Blau, {Igor W} and Gerald Wulf and Johanna Tischer and Christoph Scheid and Ahmet Elmaagacli and Helga Neidlinger and Sarah Flossdorf and Martin Bornh{\"a}user and Wolfgang Bethge and Katharina Fleischhauer and Nicolaus Kr{\"o}ger and {De Wreede}, {Liesbeth C} and Maximilian Christopeit",
year = "2024",
month = feb,
day = "1",
doi = "10.3324/haematol.2023.283175",
language = "English",
volume = "109",
pages = "431--443",
journal = "HAEMATOLOGICA",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "2",

}

RIS

TY - JOUR

T1 - Allogeneic hematopoietic stem cell transplantation in patients aged 60-79 years in Germany (1998-2018): a registry study

AU - Weller, Jan Frederic

AU - Lengerke, Claudia

AU - Finke, Jürgen

AU - Schetelig, Johannes

AU - Platzbecker, Uwe

AU - Einsele, Hermann

AU - Schroeder, Thomas

AU - Faul, Christoph

AU - Stelljes, Matthias

AU - Dreger, Peter

AU - Blau, Igor W

AU - Wulf, Gerald

AU - Tischer, Johanna

AU - Scheid, Christoph

AU - Elmaagacli, Ahmet

AU - Neidlinger, Helga

AU - Flossdorf, Sarah

AU - Bornhäuser, Martin

AU - Bethge, Wolfgang

AU - Fleischhauer, Katharina

AU - Kröger, Nicolaus

AU - De Wreede, Liesbeth C

AU - Christopeit, Maximilian

PY - 2024/2/1

Y1 - 2024/2/1

N2 - Incidences of diseases treated with transplantation frequently peak at higher age. The contribution of age to total risk of transplantation has not been estimated amidst an aging society. We compare outcomes of 1,547 patients aged 70-79 years and 9,422 patients aged 60-69 years transplanted 1998-2018 for myeloid, lymphoid and further neoplasia in Germany. To quantify the contribution of population mortality to survival, we derive excess mortality based on a sex-, year- and agematched German population in a multistate model that incorporates relapse and graft-versus-host-disease (GvHD). Overall survival, relapse-free survival (RFS) and GvHD-free-relapse-free survival (GRFS) is inferior in patients aged 70-79 years, compared to patients aged 60-69 years, with 36% (95% Confidence Interval [CI]: 34-39%) versus 43% (41-44%), 32% (30- 35%) versus 36% (35-37%) and 23% (21-26%) versus 27% (26-28%) three years post-transplant (P<0.001). Cumulative incidences of relapse at three years are 27% (25-30%) for patients aged 70-79 versus 29% (29-30%) (60-69 years) (P=0.71), yet the difference in non-relapse mortality (NRM) (40% [38-43%] vs. 35% [34-36%] in patients aged 70-79 vs. 60-69 years) (P<0.001) translates into survival differences. Median OS of patients surviving >1 year relapse-free is 6.7 (median, 95% CI: 4.5-9.4, 70-79 years) versus 9 (8.4-10.1, 60-69 years) years since landmark. Three years after RFS of one year, excess NRM is 14% (95% CI: 12-18%) in patients aged 70-79 versus 12% [11-13%] in patients aged 60-69, while population NRM is 7% (6-7%) versus 3% (3-3%). Mortality for reasons other than relapse, GvHD, or age is as high as 27% (24-29%) and 22% (22-23%) four years after transplantation. In conclusion, survival amongst older patients is adequate after allogeneic stem cell transplantation.

AB - Incidences of diseases treated with transplantation frequently peak at higher age. The contribution of age to total risk of transplantation has not been estimated amidst an aging society. We compare outcomes of 1,547 patients aged 70-79 years and 9,422 patients aged 60-69 years transplanted 1998-2018 for myeloid, lymphoid and further neoplasia in Germany. To quantify the contribution of population mortality to survival, we derive excess mortality based on a sex-, year- and agematched German population in a multistate model that incorporates relapse and graft-versus-host-disease (GvHD). Overall survival, relapse-free survival (RFS) and GvHD-free-relapse-free survival (GRFS) is inferior in patients aged 70-79 years, compared to patients aged 60-69 years, with 36% (95% Confidence Interval [CI]: 34-39%) versus 43% (41-44%), 32% (30- 35%) versus 36% (35-37%) and 23% (21-26%) versus 27% (26-28%) three years post-transplant (P<0.001). Cumulative incidences of relapse at three years are 27% (25-30%) for patients aged 70-79 versus 29% (29-30%) (60-69 years) (P=0.71), yet the difference in non-relapse mortality (NRM) (40% [38-43%] vs. 35% [34-36%] in patients aged 70-79 vs. 60-69 years) (P<0.001) translates into survival differences. Median OS of patients surviving >1 year relapse-free is 6.7 (median, 95% CI: 4.5-9.4, 70-79 years) versus 9 (8.4-10.1, 60-69 years) years since landmark. Three years after RFS of one year, excess NRM is 14% (95% CI: 12-18%) in patients aged 70-79 versus 12% [11-13%] in patients aged 60-69, while population NRM is 7% (6-7%) versus 3% (3-3%). Mortality for reasons other than relapse, GvHD, or age is as high as 27% (24-29%) and 22% (22-23%) four years after transplantation. In conclusion, survival amongst older patients is adequate after allogeneic stem cell transplantation.

U2 - 10.3324/haematol.2023.283175

DO - 10.3324/haematol.2023.283175

M3 - SCORING: Journal article

C2 - 37646665

VL - 109

SP - 431

EP - 443

JO - HAEMATOLOGICA

JF - HAEMATOLOGICA

SN - 0390-6078

IS - 2

ER -